Aradigm Appoints Amgen's Stan Benson and Aradigm's Igor Gonda, Ph.D. to Board of Directors

Apr 19, 2001, 01:00 ET from Aradigm Corporation

    HAYWARD, Calif., April 19 /PRNewswire/ --Aradigm Corporation
 (Nasdaq:   ARDM) today announced the appointment of Stan M. Benson and Igor
 Gonda, Ph.D. to its Board of Directors.  Dr. Gonda is currently the chief
 scientific officer of Aradigm and Mr. Benson is currently a senior advisor for
 sales and marketing at Amgen (Nasdaq:   AMGN).  Aradigm also announced the
 resignation of Reid Rubsamen, M.D. from its Board of Directors.
     "I am delighted to welcome Mr. Benson and Dr. Gonda to our Board of
 Directors.  For the past six years, Igor has been instrumental in putting
 together a highly regarded scientific team that has positioned Aradigm as a
 leader in the field of advanced pulmonary drug delivery," said Richard
 Thompson, chairman, president and CEO of Aradigm.  "The addition of Mr.
 Benson's expertise in managing and marketing pharmaceutical and
 biopharmaceutical products will be extremely valuable to Aradigm as we move
 forward into late-stage development of our AERx (R) pulmonary delivery
 products."
     Mr. Thompson continued, "We thank Reid for his years of dedication to
 growing Aradigm into a leading pulmonary drug delivery company and wish him
 success with his next venture.  Reid's energy and enthusiasm will be a
 positive force for any new company he is involved in."  Dr. Rubsamen is the
 founder of Aradigm and spent ten years as vice president of medical affairs in
 addition to serving on the Board.  He played an important early role in
 establishing Aradigm's technology and related intellectual property.  Dr.
 Rubsamen is now committing all of his time to a new venture outside the
 healthcare field.
     "Aradigm's unique approach to developing pulmonary drug delivery systems
 presents a very exciting opportunity," said Mr. Benson.  "I am looking forward
 to working with the Board of Directors to guide Aradigm as the company strives
 to bring new and effective pulmonary delivery products to market."
     Stan M. Benson was Amgen's senior vice president, sales and marketing from
 June 1995 until March 2001.  During his tenure, existing product sales doubled
 while Amgen's sales and marketing department grew substantially both to
 support the existing products and to prepare for the launch of innovative new
 products in the coming years.  Prior to working at Amgen, Mr. Benson worked at
 Pfizer for 19 years, where he held a number of senior management positions
 including vice president and general manager of the Pratt Pharmaceutical
 division.  Mr. Benson received a bachelor's degree in mathematics and computer
 science from New York University in 1973 and a master's degree in mathematics
 from New York University in 1975.
     Dr. Gonda, a world-renowned expert in the field of pulmonary drug
 delivery, joined Aradigm in 1995 as vice president of research and
 development.  From 1992 to 1995, he was senior scientist and group leader at
 Genentech, Inc. leading research on inhalation and other non-invasive methods
 of delivery of proteins and gene medicines.  While at Genentech, Dr. Gonda
 directed the effort to develop the pulmonary delivery systems for Pulmozyme
 (R) (dornase alfa), Genentech's product for the treatment of cystic fibrosis.
 Prior to joining Genentech, he was senior lecturer in the Department of
 Pharmacy at the University of Sydney, Australia.
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics.  The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions.  Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      AT ARADIGM CORPORATION:
      Norman Halleen
      Chief Financial Officer
      (510) 265-9000
 
      MEDIA AND INVESTORS:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577-8110
 
 

SOURCE Aradigm Corporation
    HAYWARD, Calif., April 19 /PRNewswire/ --Aradigm Corporation
 (Nasdaq:   ARDM) today announced the appointment of Stan M. Benson and Igor
 Gonda, Ph.D. to its Board of Directors.  Dr. Gonda is currently the chief
 scientific officer of Aradigm and Mr. Benson is currently a senior advisor for
 sales and marketing at Amgen (Nasdaq:   AMGN).  Aradigm also announced the
 resignation of Reid Rubsamen, M.D. from its Board of Directors.
     "I am delighted to welcome Mr. Benson and Dr. Gonda to our Board of
 Directors.  For the past six years, Igor has been instrumental in putting
 together a highly regarded scientific team that has positioned Aradigm as a
 leader in the field of advanced pulmonary drug delivery," said Richard
 Thompson, chairman, president and CEO of Aradigm.  "The addition of Mr.
 Benson's expertise in managing and marketing pharmaceutical and
 biopharmaceutical products will be extremely valuable to Aradigm as we move
 forward into late-stage development of our AERx (R) pulmonary delivery
 products."
     Mr. Thompson continued, "We thank Reid for his years of dedication to
 growing Aradigm into a leading pulmonary drug delivery company and wish him
 success with his next venture.  Reid's energy and enthusiasm will be a
 positive force for any new company he is involved in."  Dr. Rubsamen is the
 founder of Aradigm and spent ten years as vice president of medical affairs in
 addition to serving on the Board.  He played an important early role in
 establishing Aradigm's technology and related intellectual property.  Dr.
 Rubsamen is now committing all of his time to a new venture outside the
 healthcare field.
     "Aradigm's unique approach to developing pulmonary drug delivery systems
 presents a very exciting opportunity," said Mr. Benson.  "I am looking forward
 to working with the Board of Directors to guide Aradigm as the company strives
 to bring new and effective pulmonary delivery products to market."
     Stan M. Benson was Amgen's senior vice president, sales and marketing from
 June 1995 until March 2001.  During his tenure, existing product sales doubled
 while Amgen's sales and marketing department grew substantially both to
 support the existing products and to prepare for the launch of innovative new
 products in the coming years.  Prior to working at Amgen, Mr. Benson worked at
 Pfizer for 19 years, where he held a number of senior management positions
 including vice president and general manager of the Pratt Pharmaceutical
 division.  Mr. Benson received a bachelor's degree in mathematics and computer
 science from New York University in 1973 and a master's degree in mathematics
 from New York University in 1975.
     Dr. Gonda, a world-renowned expert in the field of pulmonary drug
 delivery, joined Aradigm in 1995 as vice president of research and
 development.  From 1992 to 1995, he was senior scientist and group leader at
 Genentech, Inc. leading research on inhalation and other non-invasive methods
 of delivery of proteins and gene medicines.  While at Genentech, Dr. Gonda
 directed the effort to develop the pulmonary delivery systems for Pulmozyme
 (R) (dornase alfa), Genentech's product for the treatment of cystic fibrosis.
 Prior to joining Genentech, he was senior lecturer in the Department of
 Pharmacy at the University of Sydney, Australia.
     Aradigm is working to improve the quality of life of patients by
 developing aerosol-based drug delivery alternatives to injectable
 therapeutics.  The Company's advanced pulmonary delivery technologies provide
 leading pharmaceutical and biotechnology partners with effective drug delivery
 solutions.  Current development programs focus on diabetes, pain management,
 and the pulmonary delivery of existing and emerging biotech therapeutics.
     Based in Hayward, California, Aradigm is currently developing products for
 diabetes management with Novo Nordisk A/S, the world leader in insulin and
 diabetes care, and breakthrough and acute pain management for GlaxoSmithKline,
 a world leader in oncology therapy and supportive care. In addition, Aradigm
 has four additional partner-funded programs and a gene therapy effort funded
 through the National Institutes of Health. More information about Aradigm can
 be found at www.aradigm.com. Investors may also request company information
 via email by directing inquiries to investor@aradigm.com.
 
     Please note:
     Except for the historical information contained herein, this news release
 contains forward-looking statements that involve risk and uncertainties,
 including the timely availability and acceptance of new products, the impact
 of competitive products and pricing, and the management of growth, as well as
 the other risks detailed from time to time in Aradigm Corporation's Securities
 and Exchange Commission (SEC) Registration Statements, including the company's
 Annual Report on Form 10-K as amended.
 
      AT ARADIGM CORPORATION:
      Norman Halleen
      Chief Financial Officer
      (510) 265-9000
 
      MEDIA AND INVESTORS:
      Kari Lampka
      Feinstein Kean Healthcare
      (617) 577-8110
 
 SOURCE  Aradigm Corporation